Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $2.0 million.

  • Whitehawk Therapeutics' Non-Current Assets fell 7636.88% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year decrease of 5634.62%. This contributed to the annual value of $9.0 million for FY2024, which is 1524.82% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Non-Current Assets of $2.0 million as of Q3 2025, which was down 7636.88% from $2.2 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Non-Current Assets' 5-year high stood at $9.0 million during Q4 2024, with a 5-year trough of $29452.0 in Q2 2021.
  • Over the past 5 years, Whitehawk Therapeutics' median Non-Current Assets value was $6.3 million (recorded in 2023), while the average stood at $5.2 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Non-Current Assets crashed by 8951.62% in 2021, and later skyrocketed by 1450342.25% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' Non-Current Assets (Quarter) stood at $6.6 million in 2021, then tumbled by 36.61% to $4.2 million in 2022, then surged by 86.24% to $7.8 million in 2023, then increased by 15.25% to $9.0 million in 2024, then crashed by 78.07% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.2 million for Q2 2025, and $1.4 million during Q1 2025.